MiniMed Launches IPO, Valuing Diabetes Unit at Nearly $8 Billion

GALWAY, Ireland – February 24, 2026 – Medtronic’s long-anticipated plan to reshape its corporate structure took a major step forward today as its diabetes-focused subsidiary, MiniMed Group, Inc., officially launched the roadshow for its initial public offering. The company is offering 28,000,000 shares of common stock, with an expected price range of $25.00 to $28.00 per share, signaling a potential valuation of nearly $7.9 billion for the newly independent entity.

The offering, which could raise as much as $784 million before underwriter options, marks a pivotal moment in Medtronic's strategy to spin off its diabetes business into a standalone public company. MiniMed is expected to trade on the Nasdaq Global Select Market under the ticker symbol “MMED.” Upon completion, parent company Medtronic will retain a commanding stake of approximately 90%, underscoring its continued belief in the unit's long-term value while providing it the autonomy to compete more aggressively.

A Strategic Uncoupling for Growth

This IPO is the culmination of a strategic review by Medtronic aimed at unlocking shareholder value and streamlining its vast portfolio. For years, the global healthcare technology giant has operated as a conglomerate, with divisions spanning cardiac devices, surgical robotics, and patient monitoring. The decision to separate the diabetes business reflects a broader industry trend toward creating more focused, agile companies capable of rapid innovation in highly competitive sectors.

By establishing MiniMed as an independent entity, Medtronic is betting that a dedicated management team and a singular focus on the diabetes market will accelerate growth and sharpen its competitive edge. This move follows other strategic portfolio adjustments by Medtronic, including the formation of the kidney-care joint venture Mozarc Medical with DaVita and a planned exit from the ventilator business. The strategy allows Medtronic to concentrate on its core, higher-margin businesses while giving MiniMed the freedom and financial discipline of a public company to pursue its own growth trajectory.

The separation is designed to empower MiniMed to operate with the “relentless drive of a startup,” as noted in previous company communications, enabling it to respond more nimbly to the fast-paced evolution of diabetes technology. The proceeds from the IPO will be used for general corporate purposes and to settle financial arrangements with its former parent, including the repayment of intercompany debt.

MiniMed’s Bid for Market Dominance

As it prepares for life as a public company, MiniMed is positioning itself as a unique, fully integrated player in the diabetes management space. With a 40-year history, the company is the only major competitor that develops and sells a complete ecosystem of insulin pumps, continuous glucose monitors (CGMs), and the sophisticated algorithms that connect them. This “full-stack” approach is its primary differentiator in a market of highly specialized competitors.

MiniMed has demonstrated significant momentum leading up to its market debut. Medtronic’s diabetes segment has posted six consecutive quarters of double-digit organic growth, with revenue climbing 14.8% in the most recent quarter. For its 2025 fiscal year, the division generated $2.7 billion in revenue, though it also reported a net loss of $198 million as it invested heavily in research and development.

That investment has yielded a series of critical product advancements and regulatory wins. The company’s flagship MiniMed 780G system, an automated insulin delivery (AID) platform, recently received an expanded label for use in adults with insulin-requiring type 2 diabetes, opening a vast new market. Furthermore, the FDA recently approved its next-generation Simplera Sync CGM for use with insulin pumps and cleared the pairing of the 780G pump with Abbott’s Instinct sensor, showcasing a commitment to interoperability.

Looking ahead, MiniMed’s innovation pipeline appears robust. The company has submitted its smaller MiniMed Flex insulin pump for FDA approval and is developing a patch pump, the MiniMed Fit, for submission later this year. These new form factors are designed to address patient demands for more discreet and user-friendly devices.

Navigating a Fiercely Competitive Landscape

Despite its integrated model and strong growth, MiniMed will enter the public market facing intense competition. The diabetes technology landscape is populated by formidable specialists who lead in their respective niches. In the CGM market, it will continue to battle giants like Dexcom and Abbott, whose FreeStyle Libre system has captured a significant global market share. In the insulin pump arena, it faces strong challenges from Insulet, with its popular tubeless Omnipod system, and Tandem Diabetes Care, known for its user-friendly touchscreen pumps.

These competitors have built their success on best-in-class specialization, forcing MiniMed to prove that its all-in-one ecosystem provides a superior user experience and better clinical outcomes. MiniMed’s bet is that patients and providers will prefer the seamless integration and support that comes from a single-vendor system, reducing the complexity of managing multiple devices from different manufacturers. The company's ability to innovate across all components—pumps, sensors, and software—will be critical to defending and growing its market share as an independent firm.

The Financials: Gauging Investor Appetite

The MiniMed IPO serves as a significant bellwether for investor appetite in the medtech sector, particularly for high-growth but not-yet-profitable companies. The proposed valuation of nearly $8 billion reflects confidence in the massive and growing diabetes market and MiniMed's potential to capture a larger piece of it. The offering is being led by a powerful syndicate of Wall Street's top-tier investment banks, including Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley, lending significant institutional credibility to the deal.

Investors will be closely watching the roadshow to assess the narrative presented by MiniMed’s leadership. They will weigh the company's impressive revenue growth and integrated product strategy against its current unprofitability and the fierce competitive pressures. The success of the IPO will not only determine MiniMed’s initial financial footing but also validate Medtronic's broader corporate strategy of creating value through strategic divestitures. As “MMED” prepares to make its debut, the market will soon decide what the future of this newly focused diabetes powerhouse is worth.